You are viewing: Rest Of Europe Vaccines Market analysis
Part of: Vaccines Market (Global)

The Rest Of Europe Vaccines Market was valued at $159.1 Million in 2025 and projected to reach to $231.1 Million by 2030, representing a compound annual growth rate of 7.7%. Rest Of Europe's vaccines market is positioned for robust growth, supported by strengthening healthcare systems and increased public health spending across the region.

Rest Of Europe Vaccines Market Trends and Insights

  • This 7.7% compound annual growth rate reflects increasing immunization initiatives and healthcare infrastructure improvements across the region.
  • Rest Of Latin America's vaccine market is driven by rising government investments in preventive healthcare and growing awareness of vaccine-preventable diseases among populations seeking better health outcomes. Rest Of Latin America's market dynamics are shaped by expanding vaccination programs targeting both routine immunizations and emerging infectious disease threats.
  • The forecast period through 2030 demonstrates Rest Of Latin America's commitment to strengthening its healthcare systems and vaccine accessibility.
  • Rest Of Latin America is witnessing increased participation from both public health agencies and private sector players, creating a competitive environment that supports market growth and innovation in vaccine delivery and development..

Key Market Statistics

  • CAGR (2025-2030) 7.7% CAGR
  • Market Size, 2025 ~USD 159.1 Million
  • Forecast, 2030 ~USD 231.1 Million
  • Country Rest Of Europe

Rest Of Europe Vaccines Market Overview

Market Valuation :

Rest Of Europe's vaccines market is valued at $159.1 million in 2025, demonstrating significant healthcare investment across smaller European nations and emerging markets in the region.

Strong Growth Trajectory :

With a CAGR of 7.7% through 2030, Rest Of Europe is outpacing the global average of 7.3%, indicating accelerated vaccine adoption and immunization program expansion in these markets.

Projected Market Expansion :

The market is forecasted to reach $231.1 million by 2030, representing a 45.2% increase from 2025, driven by improved healthcare infrastructure and government vaccination initiatives.

Regional Healthcare Development :

Increasing government investments in preventive healthcare and immunization programs across Rest Of Europe are strengthening vaccine accessibility and driving market penetration in underserved populations.

Rest Of Europe Vaccines Market Dynamics

  • Government-backed immunization programs and rising awareness of preventive healthcare are key growth catalysts.
  • The 7.7% CAGR reflects growing vaccine demand for both routine immunizations and emerging infectious disease prevention.
  • Market expansion is further supported by improved cold chain infrastructure and healthcare accessibility in smaller European nations, enabling broader vaccine distribution and adoption across diverse populations..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Merck KGaA
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • Rest Of Latin America's vaccines market is valued at $159.1 million in 2025 and expected to reach $231.1 million by 2030, representing a 7.7% CAGR.
    • Rest Of Latin America is experiencing increased government funding for immunization programs and preventive healthcare infrastructure development.
    • Rest Of Latin America's market growth is supported by rising disease awareness and expanding vaccination coverage across diverse populations.
    • Rest Of Latin America shows strong potential for public-private partnerships driving vaccine innovation and improved distribution networks through 2030.

    Vaccines Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment PNEUMOCOCCAL DISEASE (Disease Indication)
    Forecast Period 2025–2030
    Growth Rate CAGR of 7.3% from 2025 to 2030
    Largest Segment INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (Route Of Administration)
    Market Size Base Year (Billions) ~USD 47.75 (2025)
    Revenue Forecast (Billions) ~USD 67.91 (2030)
    Segments Covered Disease Indication, Technology, Type, Route Of Administration, End User

    Rest Of Europe Vaccines Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Disease Indication

    • Combination Vaccines
    • Covid-19
    • Dtp
    • Hepatitis
    • Herpes Zoster
    • Hpv
    • Influenza
    • Meningococcal Disease
    • Mmr
    • Other Disease Indications
    • Pneumococcal Disease
    • Polio
    • Rotavirus
    • Rsv
    • Varicella

    By Technology

    • Conjugate Vaccines
    • Inactivated & Subunit Vaccines
    • Live Attenuated Vaccines
    • Mrna Vaccines
    • Other Covid-19 Vaccines
    • Other Vaccines
    • Recombinant Vaccines
    • Toxoid Vaccines
    • Viral Vector Vaccines

    By Type

    • Monovalent Vaccines
    • Multivalent Vaccines

    By Route Of Administration

    • Intramuscular & Subcutaneous Administration
    • Oral Administration
    • Other Routes Of Administration

    By End User

    • Adult Vaccines
    • Pediatric Vaccines

    Target Audience

    • Vaccine Manufacturers : Manufacturers need Rest Of Europe-specific market data to identify growth opportunities, optimize product portfolios, and develop localized commercialization strategies for emerging European markets.
    • Healthcare Distributors : Distributors require detailed market insights to assess demand patterns, plan inventory management, and establish supply chain networks across Rest Of Europe's diverse healthcare systems.
    • Government Health Agencies : Public health officials need market intelligence to inform immunization program planning, budget allocation, and procurement strategies aligned with Rest Of Europe's vaccination targets.
    • Investment & Private Equity Firms : Investors require comprehensive market analysis and financial projections for Rest Of Europe to evaluate investment opportunities in vaccine companies, healthcare infrastructure, and immunization initiatives.
    • Healthcare Consultants : Consultants need region-specific market data to advise clients on market entry strategies, competitive positioning, and growth opportunities within Rest Of Europe's evolving vaccine landscape.

    Key Companies in the Rest Of Europe Vaccines Market

    CompanyHQOwnershipStrongest segments
    ATS AUTOMATION TOOLING SYSTEMS INCCanadaPublic CompanyEngineered automated manufacturing and assembly systems,Pre- and post-automation services,Contract manufacturing and integration services,

    ATS AUTOMATION TOOLING SYSTEMS INC

    ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 that employs approximately 7,000 people. The company specializes in automation and tooling systems for industrial applications.

    Reasons to Buy this Report

    • Regional Market Intelligence : Gain exclusive insights into Rest Of Europe's vaccine market dynamics, including country-specific growth drivers, regulatory environments, and healthcare infrastructure developments that impact vaccine adoption.
    • Competitive Positioning : Understand market share distribution, key players, and competitive strategies specific to Rest Of Europe, enabling informed business decisions and market entry strategies for vaccine manufacturers and distributors.
    • Growth Opportunity Identification : Identify high-potential segments and underserved markets within Rest Of Europe where vaccine demand is accelerating, supported by government immunization initiatives and healthcare modernization efforts.
    • Investment Decision Support : Access detailed financial projections and market valuations for Rest Of Europe through 2030, providing critical data for investment decisions, partnership evaluations, and resource allocation planning.
    • Strategic Planning Resources : Leverage comprehensive market analysis to develop targeted strategies for Rest Of Europe, including pricing models, distribution channels, and marketing approaches aligned with regional healthcare priorities.

    Frequently asked questions

    What is the current market size of vaccines in Rest Of Latin America?

    Rest Of Latin America's vaccines market is estimated at $159.1 million in 2025.

    What is the projected market size for Rest Of Latin America vaccines by 2030?

    Rest Of Latin America's vaccines market is forecasted to reach $231.1 million by 2030.

    What is the CAGR for Rest Of Latin America's vaccines market?

    Rest Of Latin America's vaccines market is expected to grow at a compound annual growth rate of 7.7% from 2025 to 2030.

    What factors are driving growth in Rest Of Latin America's vaccines market?

    Rest Of Latin America's market growth is driven by increased government investments in immunization programs, rising disease awareness, improved healthcare infrastructure, and expanding vaccination coverage initiatives.

    How is Rest Of Latin America's vaccine market structured?

    Rest Of Latin America's vaccines market comprises both public health agencies managing routine immunization programs and private sector players offering complementary vaccine services and distribution channels.

    RESEARCH METHODOLOGY

    This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global vaccines market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the vaccines market. The secondary sources used for this study include World Health Organization (WHO), the Organization for Economic Co-operation and Development (OECD), National Center for Biotechnology Information (NCBI), Centers for Disease Control and Prevention (CDC), the Global Cancer Observatory (GLOBOCAN), the National Institutes of Health (NIH), Center of Disease Control & Prevention (CDC), US Department of Health and Human Services, National Institutes of Health (NIH), National Library of Medicine, National Center for Biotechnology Information (NCBI), National Institute of Allergy and Infectious Diseases (NIAID), World Cancer Research Fund International (WCRF International), European Medicines Agency (EMA), The National Medical Products Administration (NMPA), Global Alliance for Vaccines and Immunization (GAVI), United States Food & Drug Administration (US FDA), Orange book, Purple book, Clinical trials.gov, Pan American Health Organization (PAHO), United Nation International Children’s Emergency Fund (UNICEF), Department of health and Human Services (HHS), and International Society for Vaccines (ISV). Corporate filings include annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global vaccines market, which was validated through primary research. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

    The following is a breakdown of the primary respondents:

    Vaccines Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were employed to estimate and validate the overall size of the vaccines market. These methods were also widely used to determine the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Vaccines Market

    Data Triangulation

    After estimating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown techniques were used where applicable to finalize the overall market analysis and obtain precise statistics for all segments and subsegments. The data was triangulated by examining various factors and trends from both demand and supply sides.

    Market Definition

    A vaccine is a biologically formulated product designed to trigger active acquired immunity against a specific infectious or malignant disease. Vaccines work by stimulating the immune system to identify and fight harmful agents, such as viruses or bacteria. They generally consist of parts that resemble the disease-causing microorganism, often in weakened or deactivated forms, along with their toxins or surface proteins. The report solely focuses on human vaccines and does not include veterinary vaccines, which are outside the scope of this study.

    Stakeholders

    • Vaccine product manufacturers and suppliers
    • Distributors and suppliers of vaccine products
    • Vaccine research institutes
    • Biotechnology and biopharmaceutical companies
    • Contract manufacturing organizations (CMOs)
    • Contract development and manufacturing organizations (CDMO)
    • Suppliers and distributors of pharmaceutical products
    • Research and development (R&D) companies
    • Drug Manufacturers, Vendors, and Distributors
    • Immunization centres
    • Hospitals and laboratories
    • Trade associations and industry bodies
    • Regulatory bodies and government organizations
    • Venture capitalists and investors
    • Hospitals
    • Specialty Clinics

    Report Objectives

    • To define, describe, and forecast the vaccines market by technology, type, disease indication, route of administration, end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall vaccines market
    • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
    • To profile the key players and analyze their market shares and core competencies2
    • To track and analyze competitive developments, such as product launches, agreements, partnerships, acquisitions, regulatory approvals, and research & development activities
    • To analyze and provide funding & investment activities, brand/product comparative analysis, and vendor valuation & financial metrics of the vaccines market.

    Get the Full Vaccines Market Report

    Full forecast, segment splits, and company analysis for all Vaccines Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status